USO 22095
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation (DSP-5336-101)
Disease Types: Leukemia & Lymphoma Research
Eligibility Requirements:
See Protocol for eligibility requirements.
For more information on this trial CLICK HERE .
Available at: